-Angela M Davies Researcher Activity Profile

Research Author Detailed Information 

Angela M Davies Publication Rate By Year

Angela M Davies has published 1 paper(s) in 1999, 3 paper(s) in 2002, 3 paper(s) in 2003, 1 paper(s) in 2005, 1 paper(s) in 2006, 8 paper(s) in 2007, 14 paper(s) in 2008, for a total of 31 research publications in total.

Angela M Am Davies Author Information

LAST NAME: davies

FIRST NAME: Angela M

INITIALS: am

AFFILIATION:

Papers

Angela M Davies's Publication Record

1. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). Year Published: 2007
University of California, Davis Cancer Center, Sacramento, CA 95817, USA. primo.lara@ucdmc.ucdavis.edu
2. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. Year Published: 2006
University of California, Davis, Sacramento, CA, USA. angela.davies@ucdmc.ucdavis.edu
3. The role of MR imaging in the diagnostic characterisation of appendicular bone tumours and tumour-like conditions. Year Published: 2007
Department of Radiology, The Royal National Orthopaedic Hospital, Stanmore, Middlesex, UK.
4. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. Year Published: 2007
University of California Davis Cancer Center, 4501 X Street, Sacramento, California 95817, USA.
5. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Year Published: 2007
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
6. M-LDH serves as a sarcolemmal K(ATP) channel subunit essential for cell protection against ischemia. Year Published: 2002
Tayside Institute of Child Health, Ninewells Hospital & Medical School, University of Dundee, Dundee DD1 9SY, UK.
7. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. Year Published: 2003
MRC Protein Phosphorylation Unit, School of Life Sciences, MSI/WTB Complex, University of Dundee, Dow Street, Dundee DD1 5EH, UK.
8. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. Year Published: 2007
University of California Davis Cancer Center, 4501 X Street, Sacramento, California 95817, USA.
9. 17Beta-estradiol regulates expression of K(ATP) channels in heart-derived H9c2 cells. Year Published: 2002
Tayside Institute of Child Health, Ninewells Hospital & Medical School, University of Dundee, Dundee DD1 9SY Scotland, UK.
10. Chronic mild hypoxia protects heart-derived H9c2 cells against acute hypoxia/reoxygenation by regulating expression of the SUR2A subunit of the ATP-sensitive K+ channel. Year Published: 2003
Maternal and Child Health Sciences, Tayside Institute of Child Health, Ninewells Hospital and Medical School, University of Dundee, Dundee DD1 9SY, United Kingdom.
11. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. Year Published: 2007
University of California, Davis Cancer Center, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
12. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Year Published: 2007
The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
13. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. Year Published: 2008
Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
14. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. Year Published: 2008
Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
15. Bevacizumab: optimal dose, schedule, and duration of therapy. Year Published: 2008
University of California, Davis Cancer Center Sacramento, CA.
16. Schedule-Dependent Apoptosis in K-ras Mutant Non-Small-Cell Lung Cancer Cell Lines Treated with Docetaxel and Erlotinib: Rationale for Pharmacodynamic Separation. Year Published: 2008
University of California Davis Cancer Center, Sacramento.
17. The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study. Year Published: 2008
Division of Hematology and Oncology, Davis Cancer Center, University of California, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
18. Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer. Year Published: 2007
University of California, Davis Cancer Center, Sacramento, California 95817, USA. angela.davies@ucdmc.ucdavis.edu
19. Bevacizumab: optimal dose, schedule, and duration of therapy. Year Published: 2008
20. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Year Published: 2008
University of California Davis Cancer Center, Sacramento, CA 95817, USA. angela.davies@ucdmc.ucdavis.edu
21. Regulation of sympathetic neuron differentiation by endogenous nerve growth factor and neurotrophin-3. Year Published: 2008
Life Sciences Building, School of Biosciences, Museum Avenue, Cardiff CF10 3US, Wales, United Kingdom.
22. NGF-promoted axon growth and target innervation requires GITRL-GITR signaling. Year Published: 2008
School of Biosciences, Biomedical Building, Museum Avenue, Cardiff, CF10 3US, UK.
23. Bevacizumab: optimal dose, schedule, and duration of therapy. Year Published: 2008
24. Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Year Published: 2008
University of California Davis Cancer Center, Sacramento, CA 95817, USA. angela.davies@ucdmc.ucdavis.edu
25. Risk factors for survival and local control in chondrosarcoma of bone. Year Published: 2002
Royal Orthopaedic Hospital, Northfield, Birmingham, England, UK.
26. Pencil-core granuloma of the distal radio-ulnar joint: an unusual presentation as soft-tissue sarcoma after 45 years. Year Published: 2003
Royal Orthopaedic Hospital, NHS Trust, Northfield, Birmingham, England, UK.
27. Tumour volume as a predictor of necrosis after chemotherapy in Ewing's sarcoma. Year Published: 1999
Royal Orthopaedic Hospital, Birmingham, England, UK.
28. Chondroblastoma of bone: long-term results and functional outcome after intralesional curettage. Year Published: 2005
The Royal Orthopaedic Hospital Oncology Service, Bristol Road South, Birmingham B31 2AP, UK.
29. NGF-promoted axon growth and target innervation requires GITRL-GITR signaling. Year Published: 2008
School of Biosciences, Biomedical Building, Museum Avenue, Cardiff, CF10 3US, UK.
30. Post-operative imaging of soft tissue sarcomas. Year Published: 2008
Department of Radiology, The Royal Orthopaedic Hospital, Birmingham, B31 2AP, UK. steven.james@roh.nhs.uk
31. Elastofibroma dorsi: an uncommon benign pseudotumour. Year Published: 2008
Paediatric Orthopaedic Surgery, The Royal Orthopaedic Hospital Oncology Service, Birmingham B31 2AP, UK.